Pieris Pharmaceuticals, Inc.
Symboli: PIRS
NASDAQ
11.08
USDMarkkinahinta tänään
-0.5788
P/E-suhde
0.0000
PEG-suhde
13.70M
MRK Cap
- 0.00%
DIV Tuotto
Pieris Pharmaceuticals, Inc. (PIRS) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 174.43 | 26.4 | 59.2 | 117.8 | |||||||||||
balance-sheet.row.short-term-investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.net-receivables | 11.07 | 6 | 5.8 | 3.3 | |||||||||||
balance-sheet.row.inventory | 2.1 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 37.14 | 6.3 | 8.4 | 6.5 | |||||||||||
balance-sheet.row.total-current-assets | 224.75 | 38.7 | 73.4 | 127.6 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 42.47 | 0 | 20.7 | 23 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0.65 | 0 | 1.4 | 2.9 | |||||||||||
balance-sheet.row.total-non-current-assets | 43.11 | 0 | 22.1 | 25.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.account-payables | 22.5 | 3.4 | 4.2 | 8.6 | |||||||||||
balance-sheet.row.short-term-debt | 14.09 | 0 | 0.9 | 1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 24.12 | 0 | 12.2 | 13.8 | |||||||||||
Deferred Revenue Non Current | 12.49 | 0 | 18.7 | 38.4 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -12.49 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 36.07 | 8.6 | 10.7 | 15.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 36.6 | 0 | 31 | 52.2 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 37.32 | 0 | 12.2 | 13.8 | |||||||||||
balance-sheet.row.total-liab | 154.63 | 11.9 | 67.6 | 102.8 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.37 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.retained-earnings | -1228.58 | -315 | -290.4 | -257.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.87 | 0 | -0.3 | 0.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1342.3 | 341.6 | 318.5 | 307 | |||||||||||
balance-sheet.row.total-stockholders-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 267.86 | - | - | - | |||||||||||
Total Investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.total-debt | 37.32 | 0 | 13.1 | 13.8 | |||||||||||
balance-sheet.row.net-debt | -97.65 | -17.4 | -25.5 | -103.9 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1.81 | 1.8 | 2.8 | 2.4 | |||||||||||
cash-flows.row.deferred-income-tax | 14.53 | -4.5 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 3.35 | 3.3 | 4.4 | 5.2 | |||||||||||
cash-flows.row.change-in-working-capital | -48.14 | -48.1 | -33.4 | 30.5 | |||||||||||
cash-flows.row.account-receivables | 5.31 | 5.3 | -2.6 | -1.8 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 5.7 | |||||||||||
cash-flows.row.account-payables | -0.79 | -0.8 | -4.2 | 7 | |||||||||||
cash-flows.row.other-working-capital | -12.71 | -52.7 | -26.5 | 19.6 | |||||||||||
cash-flows.row.other-non-cash-items | -0.82 | 18.3 | -0.5 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -53.82 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.acquisitions-net | -12.17 | 0 | 20.2 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -22.84 | -22.8 | -48.4 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 35.01 | 35 | 28.2 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 12.17 | 0 | -20.2 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 12 | 12 | -21.2 | -0.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -1 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 19.74 | 19.8 | 6.9 | 57.1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.07 | 0.1 | 1.3 | 2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 19.8 | 19.8 | 7.2 | 59.1 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.78 | 0.8 | -5.2 | -3.2 | |||||||||||
cash-flows.row.net-change-in-cash | -21.24 | -21.2 | -79.1 | 47.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 134.97 | 17.4 | 38.6 | 117.8 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 156.21 | 38.6 | 117.8 | 70.4 | |||||||||||
cash-flows.row.operating-cash-flow | -53.82 | -53.8 | -59.9 | -7.7 | |||||||||||
cash-flows.row.capital-expenditure | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.free-cash-flow | -53.99 | -54 | -61 | -8.6 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 42.81 | 42.8 | 25.9 | 31.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 6.49 | 1.8 | 2.8 | 2.4 | |||||||||||
income-statement-row.row.gross-profit | 36.32 | 41 | 23.1 | 29.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 41.8 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 16.85 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.operating-expenses | 55.04 | 56.9 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 55.04 | 58.7 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.interest-income | 1.85 | 1.9 | 0.7 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 3.94 | 1.8 | 8.2 | 3.7 | |||||||||||
income-statement-row.row.ebitda-caps | 3.87 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -30.74 | -15.8 | -43.5 | -51.8 | |||||||||||
income-statement-row.row.income-before-tax | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
income-statement-row.row.income-tax-expense | 12.28 | 0 | -2 | -2.4 | |||||||||||
income-statement-row.row.net-income | -23.67 | -24.5 | -31.3 | -43.4 |
Usein kysytty kysymys
Mikä on Pieris Pharmaceuticals, Inc. (PIRS) taseen loppusumma?
Pieris Pharmaceuticals, Inc. (PIRS) kokonaisvarat ovat 38680000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 20819000.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.848.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -43.657.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -0.553.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.718.
Mikä on Pieris Pharmaceuticals, Inc. (PIRS) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -24543000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 0.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 56873000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 17396000.000.